NNC 26-9100
NNC 26-9100 is a synthetic compound that has been studied for its potential effects on the central nervous system. It is primarily known for its role as a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), which is a target of interest in the treatment of type 2 diabetes mellitus and obesity.
Pharmacology[edit | edit source]
NNC 26-9100 functions by mimicking the action of the endogenous hormone glucagon-like peptide-1 (GLP-1). GLP-1 is an incretin hormone that enhances the secretion of insulin in response to meals, thereby helping to regulate blood glucose levels. By activating the GLP-1 receptor, NNC 26-9100 can potentially improve glycemic control in individuals with type 2 diabetes.
Mechanism of Action[edit | edit source]
The mechanism of action of NNC 26-9100 involves binding to the GLP-1 receptor, which is a G protein-coupled receptor (GPCR) located on the surface of pancreatic beta cells. Upon activation, this receptor stimulates the production of cyclic AMP (cAMP), leading to increased insulin secretion. Additionally, GLP-1 receptor activation can slow gastric emptying and promote satiety, which are beneficial effects for weight management.
Clinical Research[edit | edit source]
While NNC 26-9100 has shown promise in preclinical studies, its clinical efficacy and safety profile in humans require further investigation. Studies in animal models have demonstrated its potential to lower blood glucose levels and reduce body weight, but human trials are necessary to confirm these findings.
Potential Applications[edit | edit source]
The primary application of NNC 26-9100 is in the management of type 2 diabetes and obesity. By enhancing insulin secretion and promoting weight loss, it could serve as a valuable therapeutic option for patients who are unable to achieve adequate glycemic control with existing medications.
Safety and Side Effects[edit | edit source]
As with any pharmacological agent, the safety profile of NNC 26-9100 is a critical consideration. Potential side effects may include gastrointestinal disturbances, such as nausea and vomiting, which are common with GLP-1 receptor agonists. Long-term safety data are needed to fully understand the risk-benefit profile of this compound.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
